Xolair (omalizumab) works by intercepting a specific antibody in your blood called immunoglobulin E, or IgE, before it can trigger an allergic reaction. It’s a biologic medication, meaning it’s made from living cells and designed to target one precise step in the immune system rather than suppressing immunity broadly. Xolair is FDA-approved for moderate-to-severe allergic asthma, chronic hives, nasal polyps, and, as of 2024, food allergies.
The IgE Problem Xolair Solves
To understand what Xolair does, it helps to know what goes wrong during an allergic reaction. Your immune system produces IgE antibodies in response to things like pollen, pet dander, or peanut proteins. These IgE molecules don’t just float around harmlessly. They attach to receptors on the surface of two types of immune cells: mast cells (found in your skin, lungs, and gut lining) and basophils (found in your blood). Once IgE is locked onto these cells, they’re essentially armed. The next time you encounter that allergen, it cross-links the IgE molecules on the cell surface, and the cell erupts, releasing histamine and other inflammatory chemicals. That’s what causes wheezing, hives, swelling, or in severe cases, anaphylaxis.
The more IgE sitting on your mast cells and basophils, the more reactive those cells become to even small amounts of allergen. People with allergic diseases tend to have high levels of IgE, which means their immune cells are heavily armed and easily provoked.
How Xolair Blocks the Reaction
Xolair is an engineered antibody that binds to free IgE circulating in your bloodstream. It grabs onto the same region of the IgE molecule that would normally attach to receptors on mast cells and basophils. By occupying that binding site, Xolair prevents IgE from ever reaching those cells. No IgE on the cell surface means the cell can’t be triggered by allergens.
One important design feature: Xolair only binds to IgE that’s already floating free in the blood. It does not attach to IgE that’s already sitting on mast cells or basophils. This distinction matters for safety. If the drug grabbed onto cell-bound IgE, it could accidentally trigger the very reaction it’s supposed to prevent. Instead, Xolair works upstream, clearing IgE from the bloodstream so that over time, less and less of it ends up on immune cells.
The Downstream Effect on Immune Cells
Xolair’s impact goes beyond just mopping up free IgE. When there’s less IgE available in the blood, the receptors on mast cells and basophils gradually shrink in number. Immune cells adjust their surface receptors based on how much IgE is around to bind them, so as IgE levels drop, the cells dial down their receptor count. Fewer receptors means even if some IgE slips through, the cells are far less sensitive to allergen exposure.
This process doesn’t happen overnight. Basophils lose their IgE receptors relatively quickly. In one study, subjects who experienced more than an 80% reduction in basophil IgE receptors within 10 days showed a 71% decrease in their allergic response to cat allergen. Mast cells, which live in tissues rather than blood, take longer to respond. This is why Xolair’s full benefits build over weeks to months rather than appearing immediately.
What Xolair Treats
Xolair is approved for several conditions that share IgE-driven inflammation as a common thread, though not all of them involve IgE in the same way.
For allergic asthma, Xolair reduces the frequency and severity of asthma attacks by calming the IgE-mediated inflammation in the airways. It’s used as an add-on therapy when inhaled steroids and other standard treatments aren’t enough. Your dose is calculated based on your body weight and your baseline IgE level in the blood, so it varies from person to person.
For chronic hives (chronic spontaneous urticaria), Xolair helps people who break out in persistent hives that don’t respond to antihistamines. The exact role of IgE in chronic hives isn’t as straightforward as in asthma, but reducing IgE levels and calming mast cells appears to interrupt the cycle.
For nasal polyps, Xolair can shrink the growths that develop in the nasal passages and sinuses, reducing congestion and improving the sense of smell.
For food allergies, Xolair received FDA approval in 2024 to reduce the risk of allergic reactions to accidental food exposure. It doesn’t cure food allergies or allow you to eat problem foods freely. What it does is raise the threshold at which a reaction occurs, as the NIH described it, rendering immune cells “much less sensitive to stimulation by any allergen.” For someone who might react to a trace amount of peanut, Xolair can raise that threshold enough to provide a meaningful safety margin against accidental exposures. This works across multiple food allergens simultaneously, since the drug targets IgE broadly rather than being specific to one food.
How It’s Given
Xolair is delivered as a subcutaneous injection, meaning it goes just under the skin rather than into a vein. For the first several doses, you’ll receive it in a healthcare setting where providers can monitor you. The FDA has approved a prefilled syringe for self-injection at home once your provider determines it’s safe for you. Before switching to home use, your healthcare team will train you (or a caregiver) on injection technique and on recognizing signs of a serious allergic reaction.
Injections are typically given every two to four weeks, depending on the condition being treated and your individual dosing needs. For asthma, the dose and frequency depend on your body weight and IgE levels. For chronic hives, the dosing is fixed regardless of IgE.
How Long Until It Works
Xolair is not a fast-acting rescue medication. You won’t feel a difference after the first injection. The drug needs time to clear circulating IgE and allow your immune cells to gradually lose their IgE receptors. The prescribing information explicitly notes that patients may not see immediate improvement in their symptoms after starting treatment. Most people begin noticing a change within a few weeks to a few months, with continued improvement over time as the receptor downregulation process progresses.
Because of this lag, you should continue your existing medications (inhalers, antihistamines, or other treatments) while starting Xolair. Your provider will reassess your other medications over time as your symptoms improve.
Anaphylaxis Risk
Xolair carries a boxed warning for anaphylaxis, the most serious type of allergic reaction. This can present as difficulty breathing, a drop in blood pressure, fainting, hives, or swelling of the throat or tongue. About 60% to 70% of anaphylaxis cases with Xolair have occurred within the first three doses, but reactions have also been reported beyond one year of regular treatment. This is the primary reason early doses are given in a clinical setting with observation periods, and why patients who self-inject at home are trained to recognize and respond to anaphylaxis signs.